In NCT02742727, the NK-92 cell line has been engineered to express an anti-CD7 attached to TCR zeta, CD28, and 4-1BB signaling domains and to be infused in patients with CD7-positiveR/R leukemia and lymphoma to evaluate its safety and effectiveness. This evidence concerns the gene CD7 and lymphoma.